Details for Patent: 7,858,594

Which drugs does patent 7,858,594 protect, and when does it expire?

Patent 7,858,594 protects TYZEKA and is included in two NDAs.

This patent has eleven patent family members in seven countries.

Summary for Patent: 7,858,594

Title:	Crystalline and amorphous forms of beta-L-2'-deoxythymidine
Abstract:	Physical forms of beta-L-2'-deoxythymidine are disclosed that can be characterized by physical appearance, purity levels, Infra-Red and Raman spectroscopy, X-ray powder diffraction patterns, thermal properties, and methods of manufacture. These forms of beta-L-2'-deoxythymidine can be used in the manufacture of other forms of beta-L-2'-deoxythymidine, or in pharmaceutical compositions. Particularly preferred uses are in the treatment of hepatitis B.
Inventor(s):	Jonaitis; David (West Lafayette, IN), Storer; Richard (Kent, GB)
Assignee:	Novartis Pharma AG (Basel, CH)
Application Number:	12/505,839
Patent Claim Types: see list of patent claims	Compound; Formulation; Composition; Dosage form; Use;

Drugs Protected by US Patent 7,858,594

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis	TYZEKA	telbivudine	SOLUTION;ORAL	022154-001	Apr 28, 2009		DISCN	No	No			Y	Y		TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS
Novartis	TYZEKA	telbivudine	TABLET;ORAL	022011-001	Oct 25, 2006		DISCN	Yes	No			Y	Y		TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS

International Family Members for US Patent 7,858,594

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2003265396
China	100376593
China	1714098
European Patent Office	1534727
European Patent Office	2607370